Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:HIMS NYSE:NVO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHIMSHims & Hers Health$57.92+2.9%$51.55$16.05▼$72.98$12.73B2.2529.43 million shs25.87 million shsNVONovo Nordisk A/S$58.77-0.7%$55.40$45.05▼$120.56$264.19B0.6815.72 million shs11.92 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHIMSHims & Hers Health-0.78%+5.55%+32.83%+17.43%+191.31%NVONovo Nordisk A/S+6.53%+0.62%+4.67%-14.34%-49.86%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHIMSHims & Hers Health$57.92+2.9%$51.55$16.05▼$72.98$12.73B2.2529.43 million shs25.87 million shsNVONovo Nordisk A/S$58.77-0.7%$55.40$45.05▼$120.56$264.19B0.6815.72 million shs11.92 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHIMSHims & Hers Health-0.78%+5.55%+32.83%+17.43%+191.31%NVONovo Nordisk A/S+6.53%+0.62%+4.67%-14.34%-49.86%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHIMSHims & Hers Health 1.92Reduce$38.92-32.81% DownsideNVONovo Nordisk A/S 2.53Moderate Buy$77.5031.87% UpsideCurrent Analyst Ratings BreakdownLatest NVO and HIMS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/1/2025NVONovo Nordisk A/SHSBCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$70.0010/1/2025NVONovo Nordisk A/SHsbc Global ResSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy10/1/2025NVONovo Nordisk A/SHSBCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$70.009/29/2025NVONovo Nordisk A/SMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Underweight$59.00 ➝ $47.009/29/2025NVONovo Nordisk A/SZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold9/17/2025NVONovo Nordisk A/SBerenberg BankSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy9/16/2025NVONovo Nordisk A/SRothschild RedbSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy9/16/2025NVONovo Nordisk A/SRothschild & Co RedburnSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy9/12/2025HIMSHims & Hers HealthCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$68.009/9/2025NVONovo Nordisk A/SSanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform8/22/2025NVONovo Nordisk A/SDbs BankSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold(Data available from 10/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHIMSHims & Hers Health$1.48B8.87$0.36 per share159.90$2.16 per share26.81NVONovo Nordisk A/S$42.12B6.23$3.87 per share15.17$4.66 per share12.61Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHIMSHims & Hers Health$126.04M$0.80104.28111.383.809.63%26.26%13.06%11/3/2025 (Estimated)NVONovo Nordisk A/S$14.64B$3.6416.1512.612.2735.60%78.64%24.51%11/5/2025 (Estimated)Latest NVO and HIMS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025 NVONovo Nordisk A/S$0.93$0.97+$0.04$0.91$77.51 billion$11.69 billion8/4/2025Q2 2025HIMSHims & Hers Health$0.18$0.17-$0.01$0.17$550.06 million$544.83 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHIMSHims & Hers HealthN/AN/AN/AN/AN/ANVONovo Nordisk A/S$0.821.40%N/A22.53%N/ALatest NVO and HIMS DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date8/6/2025NVONovo Nordisk A/Ssemi-annual$0.41192.4%8/18/20258/18/20258/26/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHIMSHims & Hers Health1.724.984.46NVONovo Nordisk A/S0.520.780.56Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHIMSHims & Hers Health63.52%NVONovo Nordisk A/S11.54%Insider OwnershipCompanyInsider OwnershipHIMSHims & Hers Health13.71%NVONovo Nordisk A/S0.07%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHIMSHims & Hers Health1,637226.02 million195.03 millionOptionableNVONovo Nordisk A/S77,3494.47 billion4.46 billionOptionableNVO and HIMS HeadlinesRecent News About These CompaniesBMO Capital Remains a Hold on Novo Nordisk (NVO)3 hours ago | theglobeandmail.comBuy Novo Nordisk Stock as Health Names Return to Favor, Analyst SaysOctober 2 at 1:02 PM | barrons.comCan Novo Nordisk's Restructuring Program Drive its Return to Growth?October 2 at 12:16 PM | zacks.comNovo Nordisk A/S (NYSE:NVO) Upgraded by Hsbc Global Res to "Strong-Buy" RatingOctober 2 at 7:28 AM | marketbeat.comPrecision Wealth Strategies LLC Takes $913,000 Position in Novo Nordisk A/S $NVOOctober 2 at 5:16 AM | marketbeat.comNovo Nordisk A/S $NVO Stock Holdings Boosted by PFG Investments LLCOctober 2 at 4:19 AM | marketbeat.comNovo Nordisk A/S (NYSE:NVO) Trading 6.6% Higher After Analyst UpgradeOctober 2 at 2:35 AM | americanbankingnews.comCVS PBM Caremark exploring $200 copay for Novo Nordisk's Wegovy - reportOctober 1 at 12:33 AM | msn.comNovo Nordisk A/S (NYSE:NVO) Trading Up 6.6% Following Analyst UpgradeOctober 1 at 4:54 PM | marketbeat.comLevi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 30, 2025 in Novo Nordisk A/S Lawsuit – NVOOctober 1 at 4:18 PM | globenewswire.comTraders Buy High Volume of Novo Nordisk A/S Call Options (NYSE:NVO)October 1 at 2:39 PM | marketbeat.comWhy Shares in Novo Nordisk Bumped Higher TodayOctober 1 at 1:27 PM | fool.comNovo Nordisk A/S (NYSE:NVO) Rating Increased to Buy at HSBCOctober 1 at 12:24 PM | marketbeat.comClass Action Filed Against Novo Nordisk A/S (NVO) Seeking Recovery for Investors - Contact Levi & KorsinskyOctober 1 at 8:45 AM | prnewswire.comNovo Nordisk is still a 'Buy' at Goldman SachsOctober 1 at 7:44 AM | proactiveinvestors.co.ukLoudon Investment Management LLC Makes New $2.60 Million Investment in Novo Nordisk A/S $NVOOctober 1 at 6:34 AM | marketbeat.comNovo Nordisk A/S (NYSE:NVO) Upgraded by Zacks Research to "Hold" RatingOctober 1 at 5:50 AM | marketbeat.comHeartseed, Inc. Ends Partnership with Novo Nordisk, Maintains Development PlansOctober 1 at 2:31 AM | tipranks.comNVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit with the Schall Law FirmSeptember 30 at 4:41 PM | prnewswire.comLifeMD Offers Novo Nordisk’s Ozempic For $499 A Month To Eligible PatientsSeptember 30 at 1:20 PM | msn.comDenmark's Economy Wobbles as Novo Nordisk Loses SteamSeptember 30 at 1:20 PM | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025Why Datavault May Be the Penny AI Stock Investors Have Waited ForBy Nathan Reiff | September 22, 20253 Hot Tech Stocks With Bullish Charts and Ample UpsideBy Thomas Hughes | September 15, 2025Oracle Has Spoken: AI Changes EverythingBy Thomas Hughes | September 10, 2025Hims & Hers Stock Pushes to Highs on Healthcare Rate Cut FrenzyBy Gabriel Osorio-Mazilli | September 21, 2025NVO and HIMS Company DescriptionsHims & Hers Health NYSE:HIMS$57.92 +1.61 (+2.86%) Closing price 03:59 PM EasternExtended Trading$57.99 +0.07 (+0.12%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.Novo Nordisk A/S NYSE:NVO$58.77 -0.40 (-0.67%) Closing price 03:59 PM EasternExtended Trading$58.58 -0.20 (-0.34%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas How Berkshire's OxyChem Buy Cements Its Long-Term Strength NVIDIA Breaks Out to New Highs: What Comes Next? Down 22% From Highs, ServiceNow Could Be Too Cheap to Ignore Microsoft Stock Hits Stride in 2025—How Much More Can It Run? Datavault AI: The New AI Contender Backed by Big Funding General Dynamics Hits New Highs: Why It Might Keep Climbing Oklo Insiders Sell! Oh No! This Is Why Investors Shouldn’t Worry Nike’s Turnaround: If the Shoe Fits, Buy It! Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
